This clinical trial is focused on children with a condition called neurogenic bladder, which is often associated with spina bifida. Neurogenic bladder is a problem where the nerves that control the bladder do not work properly, leading to issues like frequent urination or difficulty holding urine. The study is testing a treatment using a medication called oxybutynin hydrochloride, which is delivered directly into the bladder through a process known as intravesical instillation. This method involves placing the medication directly into the bladder using a catheter, which is a thin tube. The study will compare the effects of this treatment to a placebo to see if it helps improve bladder function in children who have not responded well to other treatments taken by mouth.

The purpose of the study is to see if the intravesical use of oxybutynin can increase the bladder’s capacity to hold urine, which could help reduce symptoms like frequent urination or incontinence. Children participating in the study will receive either the oxybutynin treatment or a placebo for a period of four weeks. During this time, researchers will monitor changes in the bladder’s ability to hold urine and any side effects that may occur. The study aims to provide a better understanding of whether this treatment can be a more effective option for children with neurogenic bladder who have not had success with oral medications.

Throughout the study, participants will undergo regular check-ups to assess their bladder function and overall health. The study will also evaluate how well the treatment is tolerated by the children, looking at any potential side effects such as digestive or neurological issues. By the end of the study, researchers hope to determine if intravesical oxybutynin is a safe and effective treatment option for improving bladder function in children with neurogenic bladder due to spina bifida.